市場調查報告書
商品編碼
1349209
異種移植市場規模 - 按產品類型(器官保存解決方案、移植診斷、異種產品)、按應用(腎、心、肝、肺)、按最終用途 - 到2032年的全球預測Xenotransplantation Market Size - By Product Type (Organ Preservation Solution, Transplant Diagnostics, Xeno Products), By Application (Kidney, Heart, Liver, Lung), By End-use- Global Forecast to 2032 |
2023年至2032年間,全球異種移植市場的年複合成長率將達到 8.9%。用於移植的人體器官持續短缺,迫切需要替代解決方案。異種移植,即將動物的器官或組織移植到人類身上,在這方面提供了一條有前途的途徑。基因工程的進步使得基因改造豬的發展成為可能,其器官與人類免疫系統更相容。這項突破促進了異種移植的研究和投資。
領先公司之間不斷成長的合作夥伴關係也支持了異種移植市場的前景。例如,2023年 4月,傳染病診斷領域的知名人士 Karius 與異種移植領域的拓荒者 eGenesis 建立了合作關係。此次合作將重點開發專為異種移植設計的傳染病診斷方法。
整個異種移植市場根據產品、應用、最終用途和地區進行分類。
在產品方面,器官保存解決方案細分從2023年到2032年將呈現8.8%的年複合成長率。隨著異種移植領域探索利用動物器官進行人體移植,對有效的保存方法的需求非常重要。器官保存解決方案在運輸和移植過程中維持收穫器官的活力和功能方面發揮著非常重要的作用。延長器官保存期限、提高移植成功率和解決人類捐贈器官嚴重短缺的潛力使其在異種移植市場中被採用。
在應用方面,2023年至2032年,肺臟細分的年複合成長率將達到8.6%。肺移植仍然是終末期肺病患者的迫切需求,而合適的人體供體器官的短缺是一個持續的挑戰。異種移植,包括使用基因改造豬肺,提供了一個潛在的解決方案。擴大可用器官庫、改善等待名單結果並最終挽救更多生命的承諾推動了對異種移植肺的需求不斷成長。
就最終用途而言,從2023年到2032年,醫院細分的年複合成長率將達到 9.1%。異種移植包括將動物的器官或組織移植到人類體內,為接受救生手術的患者帶來了希望。隨著等待器官移植的患者數量不斷增加,醫院探索這種創新方法來擴大可用器官庫,並支持異種移植市場收入。
從地區來看,2023年至2032年,歐洲異種移植產業的年複合成長率將達到9.1%。該大陸面臨與世界其他地區類似的挑戰,用於移植的人類捐贈者器官短缺。因此,醫學界擴大探索異種移植作為可行的解決方案。不斷增加的研究投資、有利的監管發展以及對推動醫學科學的承諾是這項需求的促進因素。歐洲透過異種移植積極主動地解決器官短缺問題,凸顯了該地區致力於改善患者治療效果和滿足關鍵醫療保健需求的決心。
Global Xenotransplantation Market will witness an 8.9% CAGR between 2023 and 2032. A persistent shortage of human organs for transplantation has created a pressing need for alternative solutions. Xenotransplantation, the transplantation of organs or tissues from animals into humans, presents a promising avenue in this regard. Advancements in genetic engineering have enabled the development of genetically modified pigs, whose organs are more compatible with the human immune system. This breakthrough has bolstered research and investment in xenotransplantation.
The growing partnerships between leading companies also support the xenotransplantation market outlook. For instance, in April 2023, Karius, a prominent player in infectious disease diagnostics, entered a collaboration with eGenesis, a trailblazer in xenotransplantation. This partnership will focus on the development of infectious disease diagnostics specifically designed for xenotransplantation.
The overall Xenotransplantation Market is classified based on product, application, end-use, and region.
In terms of product, the organ preservation solution segment will demonstrate an 8.8% CAGR from 2023 to 2032. As the field of xenotransplantation explores the use of animal organs for human transplantation, the need for effective preservation methods is paramount. Organ preservation solutions play a crucial role in maintaining the viability and functionality of harvested organs during transportation and transplantation procedures. The potential to extend the shelf life of organs, improve transplant success rates, and address the critical shortage of human donor organs leads to its adoption in the xenotransplantation market.
With respect to application, the lung segment will register an 8.6% CAGR from 2023 to 2032. Lung transplantation remains a critical need for patients with end-stage lung diseases, and the shortage of suitable human donor organs is a persistent challenge. Xenotransplantation, involving the use of genetically modified pig lungs, offers a potential solution. The increasing demand for xenotransplanted lungs is driven by the promise of expanding the pool of available organs, improving waiting list outcomes, and ultimately saving more lives.
Regarding end-use, the hospitals segment will showcase a 9.1% CAGR from 2023 to 2032. Xenotransplantation, which involves transplanting organs or tissues from animals into humans, offers hope to patients undergoing life-saving procedures. With an increasing number of patients awaiting organ transplants, hospitals are exploring this innovative approach to expand the pool of available organs, supporting the xenotransplantation market revenue.
Regionally, Europe xenotransplantation industry will record a 9.1% CAGR from 2023 to 2032. The continent faces similar challenges as the rest of the world, with a shortage of human donor organs for transplantation. As a result, the medical community is increasingly exploring xenotransplantation as a viable solution. Growing investment in research, favorable regulatory developments, and a commitment to advancing medical science are driving factors in this demand. Europe's proactive approach to addressing organ shortages through xenotransplantation highlights the region's dedication to improving patient outcomes and addressing critical healthcare needs.